MNG1087
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.204
- MYOGENESIS+0.192
- ALLOGRAFT_REJECTION+0.121
- MYC_TARGETS_V2+0.107
- UV_RESPONSE_UP+0.096
- KRAS_SIGNALING_DN+0.094
- WNT_BETA_CATENIN_SIGNALING+0.072
- COAGULATION+0.052
- IL2_STAT5_SIGNALING+0.039
- P53_PATHWAY+0.029
Top 10 suppressed
- PROTEIN_SECRETION-0.539
- MTORC1_SIGNALING-0.444
- G2M_CHECKPOINT-0.435
- ANGIOGENESIS-0.407
- MYC_TARGETS_V1-0.406
- E2F_TARGETS-0.393
- ANDROGEN_RESPONSE-0.388
- GLYCOLYSIS-0.352
- UV_RESPONSE_DN-0.318
- UNFOLDED_PROTEIN_RESPONSE-0.273
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454742 | — | D | 0.855 |
| 2 | MNG1243 | — | — | 0.853 |
| 3 | MNG1245 | — | — | 0.848 |
| 4 | MNG1258 | — | — | 0.840 |
| 5 | R39 | — | — | 0.832 |
| 6 | R96 | — | — | 0.822 |
| 7 | MNG1092 | — | — | 0.813 |
| 8 | 9176b038-65e3-469d-a867-d99bc732e45d | — | — | 0.813 |
| 9 | d406bb03-1a9a-4aa3-a1a8-4de5478b4701 | — | — | 0.806 |
| 10 | TCGA-LD-A7W5-01A-22R-A352-07 | — | A | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.204 | Inavolisib | — uncovered |
| MYOGENESIS | 0.192 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.121 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.107 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.096 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.094 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.072 | Inavolisib | — uncovered |
| COAGULATION | 0.052 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.039 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.029 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.023 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.022 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.021 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.007 | Inavolisib | — uncovered |